Vimarsana
Biggest News Aggregation in the World

Page 10 - Alkermes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alkermes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alkermes Today - Breaking & Trending Today

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says - Vimarsana News

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says

On Tuesday, Alkermes plc ALKS revealed topline results from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a phase 1b,…

Source: biztoc.com
BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024 - Vimarsana News

BlackBerry, Alkermes rise; Neogen, Tilray Brands fall, Tuesday, 4/9/2024

Stocks that are trading heavily or have substantial price changes on Tuesday: BlackBerry, Alkermes rise; Neogen, Tilray Brands fall.

Source: biztoc.com
Related Topics:
Tilray Brands
Psychiatry drugs finally have pharma's attention. Can they keep it? - Vimarsana News

Psychiatry drugs finally have pharma's attention. Can they keep it?

BioPharma

China Universal Asset Management Co. Ltd. Acquires 15,035 Shares of Alkermes plc (NASDAQ:ALKS) - Vimarsana News

China Universal Asset Management Co. Ltd. Acquires 15,035 Shares of Alkermes plc (NASDAQ:ALKS)

China Universal Asset Management Co. Ltd. boosted its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 352.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,306 shares of the company’s stock after buying an additional 15,035 shares during the quarter. China […]

Schizophrenia Market Size and Trends – Exploring Projected Outlook and Growth for 2033 | Marketresea - Vimarsana News

Schizophrenia Market Size and Trends – Exploring Projected Outlook and Growth for 2033 | Marketresea

Marketresearch.biz reports that the Increasing incidence of schizophrenia in developed economies, growing awareness among individuals about treatments for schizophrenia, and increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving the growth of the global schizo...